. 2022 Feb 9;29(5):1538–1544. doi: 10.1111/ene.15265

TABLE 2.

Predictors of seroconversion after SARS‐CoV‐2 vaccination

Whole cohort	Seropositivity ^a
Whole cohort	OR	95% CI	p value
Age (per 5 years)	0.99	0.96–1.01	0.271
DMT ^a
N‐DMT	0.90	0.15–5.5	0.905
IM‐DMT	0.83	0.18–3.8	0.812
IS‐DMT	0.04	0.01–0.13	<0.001
Lymphocyte count (per 0.1 G/L)	1.14	0.88–1.59	0.234
	R squared 0.573; p < 0.001
Subgroup analyses ^b
S1PM subgroup
S1PMs	0.05	0.01–0.23	<0.001
Lymphocyte count (per 0.1 G/L)	1.31	1.02–1.77	0.035
CD20 mAb subgroup
CD20 mAbs	0.03	0.01–0.14	<0.001
Complete B‐cell depletion ^c	0.52	0.24–0.93	0.038
Time since last DMT intake (per month)	1.24	0.56–4.13	0.739
Subgroup ATZ/CLA
ATZ/CLA	0.18	0.03–0.99	0.049
Lymphocyte count (per 0.1 G/L)	1.24	0.72–2.82	0.608
Time since last DMT intake (per month)	1.38	1.06–1.98	0.026

Abbreviations: ATZ, alemtuzumab; CLA, cladribine; CI, confidence interval; CD20 mAbs, anti‐cluster of differentiation 20 monoclonal antibodies; DMT, disease‐modifying treatment; IM‐DMT, immunomodulating DMT; IS‐DMT, immunosuppressive DMT; MS, multiple sclerosis; N‐DMT, untreated; OR, odds ratio; S1PMs, sphingosin 1 receptor modulators.

^{^a}

Reference category: healthy controls.

^{^b}

Predefined subgroup analyses of patients on S1PMs, CD20 mAbs and the combined group of ATZ and CLA vs. N‐DMT as the reference category, calculated by multivariable binary logistic regression models with seroconversion as the dependent variable and DMT group as the independent variable, and with age, sex, disease duration, time interval to last DMT intake as well as absolute lymphocyte count (for S1PM and ATZ+CLA subgroups) or complete B‐cell depletion (for the CD20‐mAb subgroup) as covariates.

^{^c}

Reference category: incomplete B‐cell depletion.